Main
/Trials
Found:
10 trials shown from 1179 total

Biomarkers in Samples From Patients With Endometrial Cancer

Estimated study start date: 31 January 2100

This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn mor

Study number:
NCT01199250
Cohorts:
1
Study phase:
N/A
Overall status:
Not yet recruiting
Study type:
Observational, Biomarker

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Estimated study start date: 6 February 2024

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally advanced or metastatic squamous N

Study number:
NCT05910827
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Chemotherapy, Targeted therapy

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Estimated study start date: 1 December 2023

This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

Study number:
NCT02633514
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Local/Regional therapies, Chemotherapy

Astrazeneca

Key trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Estimated study start date: 23 November 2023

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investig

Study number:
NCT06103864
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Estimated study start date: 16 November 2023

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who r

Study number:
NCT05920356
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Chemotherapy, Targeted therapy

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Estimated study start date: 31 October 2023

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for th

Study number:
NCT05696626
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy

Astrazeneca

Key trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Estimated study start date: 5 October 2023

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer wit

Study number:
NCT05952557
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Hormonal therapy

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

Estimated study start date: 30 August 2023

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be

Study number:
NCT05929885
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Any

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Estimated study start date: 17 August 2023

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab

Study number:
NCT06007937
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Biomarker, Targeted therapy

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Estimated study start date: 1 August 2023

The objective of this study is to determine overall response rate to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.

Study number:
NCT05773092
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Targeted therapy